# A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

> **NCT04451772** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 185 (actual)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** Elsubrutinib
- **DRUG:** Placebo for Elsubrutinib
- **DRUG:** Upadacitinib
- **DRUG:** Placebo for Upadacitinib

## Key facts

- **NCT ID:** NCT04451772
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2024-01-03
- **Final completion:** 2024-01-03
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04451772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04451772, "A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04451772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*